Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to ...

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Moderna is counting on new mRNA products such as its experimental COVID-flu combo shot to offset slumping COVID vaccine sales ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The company last reported total revenues of $108M in Q1, down 35.3% Y/Y due to lower net product sales, particularly its ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...